biogen_logo

Biogen Q1 profits rise boosted by Tecfidera sales

pharmafile | April 22, 2016 | News story | Medical Communications, Sales and Marketing Biogen, Q1, biotech, earnings, results, tecfidera 

Shares in Biogen (Nasdaq: BIIB) climbed to close up over 5% Thursday after the company reported 18% rise in first-quarter profit driven by sales of multiple-sclerosis drug Tecfidera.

The biotech firm reported profit of $970.9 million, or $4.43 a share, up from $822.5 million, or $3.49 a share, a year earlier.

Excluding charges from restructuring and other items, adjusted per-share earnings rose to $4.79 from $3.82 a year earlier. Revenue grew 6.7% to $2.73 billion, the company said in a statement.

Advertisement

Chief Executive George Scangos, said: “Our leading multiple sclerosis portfolio, a growing hemophilia business, and our ongoing focus on managing expenses led to robust earnings growth in the first quarter.”

The company is developing treatments for Alzheimer’s disease and multiple sclerosis.

Scangos said: “The remainder of 2016 will be an exciting period as we look to advance a number of potential breakthrough therapies in the clinic. We are executing Phase III clinical trials for aducanumab in early Alzheimer’s disease and, along with our collaboration partner Ionis, we are progressing nusinersen in spinal muscular atrophy. In the coming months, we expect opicinumab (anti-LINGO) Phase II data to provide us with a better understanding of its potential as a reparative therapy for multiple sclerosis.”

Sales for multiple sclerosis drug Avonex dropped 19% to $564 million in the first quarter, down from $693 million a year ago. 

Anjali Shukla

Related Content

Cellbyte raises $2.75m to fund pharma drug launch platform

Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Lilly opens fourth US Gateway Labs site

Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content